Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi.
Drug Res (Stuttg). 2021 Apr;71(4):173-179. doi: 10.1055/a-1291-7692. Epub 2021 Jan 12.
Coronavirus disease (COVID-19) emerged from Wuhan, has now become pandemic and the mortality rate is growing exponentially. Clinical complication and fatality rate is much higher for patients having co-morbid issues. Compromised immune response and hyper inflammation is hall mark of pathogenesis and major cause of mortality. Cytokine release syndrome (CRS) or cytokine storm is a term used to affiliate the situation of hyper inflammation and therefore use of anti-cytokine and anti-inflammatory drugs is used to take care of this situation. Looking into the clinical benefit of these anti-inflammatory drugs, many of them enter into clinical trials. However, understanding the immunopathology of COVID-19 is important otherwise, indiscriminate use of these drugs could be fetal as there exists a very fine line of difference between viral clearing cytokines and inflammatory cytokines. If any drug suppresses the viral clearing cytokines, it will worsen the situation and hence, the use of these drugs must be based on the clinical condition, viral load, co-existing disease condition and severity of the infection.
冠状病毒病 (COVID-19) 源自武汉，现已成为全球性大流行病，死亡率呈指数级增长。合并症患者的临床并发症和死亡率要高得多。免疫反应受损和过度炎症是发病机制的标志，也是主要死亡原因。细胞因子释放综合征 (CRS) 或细胞因子风暴是用于关联过度炎症情况的术语，因此使用抗细胞因子和抗炎药物来处理这种情况。考虑到这些抗炎药物的临床益处，许多药物已进入临床试验。然而，了解 COVID-19 的免疫病理学非常重要，否则，这些药物的滥用可能会产生不良后果，因为清除病毒的细胞因子和炎症细胞因子之间存在着非常细微的差异。如果任何药物抑制了清除病毒的细胞因子，病情将会恶化，因此，这些药物的使用必须基于临床状况、病毒载量、共存疾病状况和感染的严重程度。
